{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:38:12Z","timestamp":1792715892122,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013119","name":"PharmaMar SA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013119","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.esmoop.2026.108534","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T21:04:52Z","timestamp":1789419892000},"page":"108534","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Lurbinectedin plus irinotecan in pretreated gastroenteropancreatic neuroendocrine neoplasms: results of a phase II expansion cohort"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3342-397X","authenticated-orcid":false,"given":"R.","family":"Garcia-Carbonero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0181-886X","authenticated-orcid":false,"given":"G.M.","family":"Cote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Le Cesne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9237-8614","authenticated-orcid":false,"given":"B.","family":"Ant\u00f3n-Pascual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8966-7236","authenticated-orcid":false,"given":"T.","family":"Alonso-Gordoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4531-5877","authenticated-orcid":false,"given":"A.","family":"Falcon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gil-Torralvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Kahatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0150-2390","authenticated-orcid":false,"given":"V.","family":"Alfaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Zubiaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Jimenez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Siguero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4616-0598","authenticated-orcid":false,"given":"J.","family":"Molina-Cerrillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2026.108534_bib1","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1210\/endrev\/bnad006","article-title":"Advances in the treatment of gastroenteropancreatic neuroendocrine carcinomas: are we moving forward?","volume":"44","author":"Garcia-Carbonero","year":"2023","journal-title":"Endocr Rev"},{"key":"10.1016\/j.esmoop.2026.108534_bib2","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1159\/000443172","article-title":"ENETS consensus guidelines for high-grade gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas","volume":"103","author":"Garcia-Carbonero","year":"2016","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.esmoop.2026.108534_bib3","doi-asserted-by":"crossref","DOI":"10.1111\/jne.70080","article-title":"Controversies in NEN: an ENETS position statement on the treatment of patients with grade 3 well-differentiated neuroendocrine tumours of the gastro-enteropancreatic tract","volume":"37","author":"McNamara","year":"2025","journal-title":"J Neuroendocrinol"},{"key":"10.1016\/j.esmoop.2026.108534_bib4","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/s41416-025-03054-w","article-title":"Characteristics and treatment outcome in a prospective cohort of 639 advanced high-grade digestive neuroendocrine neoplasms (NET G3 and NEC). The NORDIC NEC 2 study","volume":"133","author":"Sorbye","year":"2025","journal-title":"Br J Cancer"},{"key":"10.1016\/j.esmoop.2026.108534_bib5","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1470-2045(23)00001-3","article-title":"Bevacizumab plus FOLFIRI after failure of platinum-etoposide first-line chemotherapy in patients with advanced neuroendocrine carcinoma (PRODIGE 41-BEVANEC): a randomised, multicentre, non-comparative, open-label, phase 2 trial","volume":"24","author":"Walter","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2026.108534_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102015","article-title":"NET-02: a randomised, non-comparative, phase II trial of nal-IRI\/5-FU or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma","volume":"60","author":"McNamara","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.esmoop.2026.108534_bib7","doi-asserted-by":"crossref","first-page":"6657","DOI":"10.1158\/0008-5472.CAN-16-0568","article-title":"Lurbinectedin inactivates the Ewing sarcoma oncoprotein EWS-FLI1 by redistributing it within the nucleus","volume":"76","author":"Harlow","year":"2016","journal-title":"Cancer Res"},{"issue":"suppl 8","key":"10.1016\/j.esmoop.2026.108534_bib8","article-title":"Lurbinectedin (PM01183) synergizes with topoisomerase I inhibitors in vitro and in vivo","volume":"73","author":"Galmarini","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.esmoop.2026.108534_bib9","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1158\/1535-7163.MCT-16-0172","article-title":"Lurbinectedin specifically triggers the degradation of phosphorylated RNA polymerase II and the formation of DNA breaks in cancer cells","volume":"15","author":"Santamaria Nu\u00f1ez","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.esmoop.2026.108534_bib10","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/biot.200900174","article-title":"In vivo bioassay to detect irinotecan-stabilized DNA\/topoisomerase I complexes in rats","volume":"5","author":"Barth","year":"2010","journal-title":"Biotechnol J"},{"key":"10.1016\/j.esmoop.2026.108534_bib11","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1007\/s10637-025-01583-y","article-title":"Phase I results on the efficacy, safety and pharmacokinetics of lurbinectedin and irinotecan in advanced solid tumors","volume":"43","author":"Falc\u00f3n","year":"2025","journal-title":"Invest New Drugs"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2026.108534_bib12","doi-asserted-by":"crossref","first-page":"8094","DOI":"10.1200\/JCO.2024.42.16_suppl.8094","article-title":"Efficacy and safety of lurbinectedin (LUR) with irinotecan (IRI) in patients (Pts) with relapsed small cell lung cancer (SCLC): results from a phase 2 expansion cohort","volume":"42","author":"Paz-Ares","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108534_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2026.103654","article-title":"Combination of lurbinectedin plus irinotecan: preclinical and early clinical results in relapsed small cell lung cancer patients","volume":"21","author":"Ponce","year":"2026","journal-title":"J Thorac Oncol"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2026.108534_bib14","doi-asserted-by":"crossref","first-page":"11560","DOI":"10.1200\/JCO.2024.42.16_suppl.11560","article-title":"Efficacy and safety of lurbinectedin (LUR) with irinotecan (IRI) in a phase 2 expansion cohort of patients (Pts) with synovial sarcoma (SS)","volume":"42","author":"Cote","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108534_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102416","article-title":"27O Lurbinectedin plus irinotecan in pre-treated gastroenteropancreatic neuroendocrine carcinomas (GEP-NECs)","volume":"9","author":"Garcia-Carbonero","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmoop.2026.108534_bib16","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.ejca.2022.06.024","article-title":"Lurbinectedin in patients with pretreated neuroendocrine tumours: results from a phase II basket study","volume":"172","author":"Longo-Mu\u00f1oz","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2026.108534_bib17","first-page":"178","article-title":"Lurbinectedin (PM01183) in combination with doxorubicin (DOX): preliminary results of a phase Ib study","volume":"49","author":"Calvo","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2026.108534_bib18","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1158\/1078-0432.CCR-20-3901","article-title":"FDA approval summary: lurbinectedin for the treatment of metastatic small cell lung cancer","volume":"27","author":"Singh","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2026.108534_bib19","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2025.2584898","article-title":"FDA approves lurbinectedin in combination with atezolizumab for extensive-stage small cell lung cancer","volume":"14","author":"Kepp","year":"2025","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.esmoop.2026.108534_bib20","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2026.44.16_suppl.e20115","article-title":"Evaluation of atezolizumab, durvalumab, lurbinectedin, and tarlatamab in high-grade extrapulmonary neuroendocrine carcinoma: a multicenter retrospective comparative analysis","volume":"44","author":"Moore","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108534_bib21","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2026.108534_bib22","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/his.13975","article-title":"The 2019 WHO classification of tumours of the digestive system","volume":"76","author":"Nagtegaal","year":"2020","journal-title":"Histopathology"},{"key":"10.1016\/j.esmoop.2026.108534_bib23","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920915299","article-title":"Second-line treatment in patients with advanced extra-pulmonary poorly differentiated neuroendocrine carcinoma: a systematic review and meta-analysis","volume":"12","author":"McNamara","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.esmoop.2026.108534_bib24","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13249","article-title":"European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for digestive neuroendocrine carcinoma","volume":"35","author":"Sorbye","year":"2023","journal-title":"J Neuroendocrinol"},{"key":"10.1016\/j.esmoop.2026.108534_bib25","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","article-title":"Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study","volume":"387","author":"Yao","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2026.108534_bib26","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11523-020-00784-0","article-title":"Updated efficacy and safety outcomes for patients with well-differentiated pancreatic neuroendocrine tumors treated with sunitinib","volume":"16","author":"Fazio","year":"2021","journal-title":"Target Oncol"},{"key":"10.1016\/j.esmoop.2026.108534_bib27","doi-asserted-by":"crossref","DOI":"10.1177\/17588359241290140","article-title":"SUNLAND: a randomized, double-blinded phase II GERCOR trial of sunitinib versus placebo and lanreotide in patients with advanced progressive midgut neuroendocrine tumors","volume":"16","author":"Hammel","year":"2024","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.esmoop.2026.108534_bib28","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","article-title":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumors","volume":"364","author":"Raymond","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2026.108534_bib29","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa2403991","article-title":"Phase 3 trial of cabozantinib to treat advanced neuroendocrine tumors","volume":"392","author":"Chan","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2026.108534_bib30","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of (177)Lu-dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2026.108534_bib31","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","volume":"403","author":"Singh","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2026.108534_bib32","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1200\/JCO.22.01013","article-title":"Randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors (ECOG-ACRIN E2211)","volume":"41","author":"Kunz","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108534_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105922","article-title":"Streptozotocin plus 5-fluorouracil followed by everolimus or the reverse sequence in patients with advanced pancreatic neuroendocrine tumors (SEQTOR-GETNE phase III study): a randomized clinical trial","volume":"10","author":"Capdevila","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmoop.2026.108534_bib34","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ctrv.2016.01.005","article-title":"Chemotherapy for advanced non-pancreatic well-differentiated neuroendocrine tumours of the gastrointestinal tract, a systematic review and meta-analysis: a lost cause?","volume":"44","author":"Lamarca","year":"2016","journal-title":"Cancer Treat Rev"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2026.108534_bib35","article-title":"A phase III study of lurbinectedin alone or in combination with irinotecan vs investigator\u2019s choice (topotecan or irinotecan) in patients with relapsed small cell lung cancer (SCLC; LAGOON trial)","volume":"41","author":"Besse","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108534_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113259","article-title":"Pooled safety analysis of single-agent lurbinectedin in patients with advanced solid tumours","volume":"192","author":"Leary","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2026.108534_bib37","first-page":"13","article-title":"Irinotecan versus infusional 5-fluorouracil: a phase III study in metastatic colorectal cancer following failure on first-line 5-fluorouracil. V302 study group","volume":"26","author":"Van Cutsem","year":"1999","journal-title":"Semin Oncol"},{"key":"10.1016\/j.esmoop.2026.108534_bib38","first-page":"6","article-title":"A phase III study of irinotecan (CPT-11) versus best supportive care in patients with metastatic colorectal cancer who have failed 5-fluorouracil therapy. V301 study group","volume":"26","author":"Cunningham","year":"1999","journal-title":"Semin Oncol"},{"key":"10.1016\/j.esmoop.2026.108534_bib39","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1158\/1078-0432.CCR-09-1526","article-title":"A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan","volume":"16","author":"van der Bol","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2026.108534_bib40","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.lungcan.2007.12.003","article-title":"Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer","volume":"63","author":"Han","year":"2009","journal-title":"Lung Cancer"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926024798?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926024798?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:42:45Z","timestamp":1792712565000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926024798"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2059702926024798"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108534","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lurbinectedin plus irinotecan in pretreated gastroenteropancreatic neuroendocrine neoplasms: results of a phase II expansion cohort","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108534","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"108534"}}